-
By Barbara A. Phillips, MD, MSPH
Professor of Medicine, University of Kentucky; Director, Sleep Disorders Center, Samaritan Hospital, Lexington, KY Dr. Phillips serves on the speakers bureau of Cephalon, Boehringer Ingelheim, Merck, ResMed, and GlaxoSmithKline and is a consultant for Boehringer Ingelheim, Wyeth-Ayerst, and ResMed.
Synopsis: There was no overall effect of 100 mg aspirin every other day on total cancer among nearly 40,000 women randomized to aspirin or placebo and followed for an average of 10 years.
-
By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD
Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; Asst. Clinical Professor of Medicine, University of California, San Francisco; Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA
Drs. Chan and Elliott report no financial relationships to this field of study.
-
By Malcolm Robinson, MD, FACP, FACG
Emeritus Clinical Professor of Medicine, University of Oklahoma College of Medicine, Oklahoma City, OK
Disclosure; Dr. Robinson serves as a consultant for TAP, Pfizer, Janssen, Eisai, J&J-Merck, and Procter & Gamble, is on the speakers bureau of Janssen, Eli Lilly, Solvay, TAP, and Aventis, and does research for Forest Labs, Wyeth-Ayerst, AstraZeneca,and Centocor.
Synopsis: Rifaximin, a newly released nonabsorbed antibiotic, appears to safely and effectively prevent the onset and substantial morbidity of travelers diarrhea.
-
By Harold L. Karpman, MD
Clinical Professor of Medicine, UCLA School of Medicine
Disclosure; Dr. Karpman reports no financial conflicts of interest in this field of study.
Despite the recent explosion of pharmacologic agents available for the treatment of congestive heart failure (CHF), many patients continue to be severely symptomatic and their prognosis remains poor.
-
By Joseph E. Scherger, MD, MPH
Clinical Professor, University of California, San Diego
Disclosure; Dr. Scherger reports no financial conflicts to this field of study.
-
By Ralph R. Hall, MD, FACP
Emeritus Professor of Medicine, University of Missouri, Kansas City School of Medicine
Disclosure; Dr. Hall is a consultant for Sanofi-Aventis.
Synopsis: Exercise and stress management improved markers of cardiovascular disease more than usual care alone.
-
White-Coat HTN
Make Diabetics Walk
Treatment of Complicated Grief
-
By Norman R. Relkin, MD, PhD
Associate Professor of Clinical Neurology and Neuroscience at New York Presbyterian Hospital-Cornell Campus.
Dr. Relkin is on the speaker's bureau of Pfizer, Eisai, and Athena Diagnostics and does research for Pfizer and Merck.
-
Rifamixin, a nonabsorbed oral antibiotic, is effective for preventing traveler's diarrhea, according to new research.
-
By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD
Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; Associate Clinical Professor of Medicine, University of California, San Francisco; Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA. Drs. Chan and Elliott report no financial relationships to this field of study.
A synthetic analog of human amylin has been approved for the treatment of type 1 and type 2 diabetics.
Pramlintide is a 37-amino acid peptide which differs from human amylin with substitution of three amino acids at positions 25, 28, and 29. It represents the first of a new class of amylinomimetic antidiabetic compounds. It is marketed by Amylin Pharmaceuticals, Inc as Symlin.
